Incidence and management of gynecomastia in men treated for prostate cancer

Adrian S Dobs, Malcolm J M Darkes

Research output: Contribution to journalArticle

Abstract

Purpose: Gynecomastia is a potentially treatment limiting adverse event in men receiving hormone therapy for prostate cancer. Materials and Methods: In large, randomized, placebo controlled studies approximately 50% or more of patients with prostate cancer experienced gynecomastia due to multiple mechanisms. Although its severity was mostly reported as mild to moderate, gynecomastia was cited as the reason for most premature withdrawals from therapy. In patients with advanced forms of prostate cancer bilateral orchiectomy was associated with the lowest incidence of gynecomastia, followed by nonsteroidal antiandrogen therapy, diethylstilbestrol and estrogen in rank order. Results: It is important that gynecomastia is well managed in patients with prostate cancer who want to proceed with hormone therapy. Patients should be assessed for the likely etiology of gynecomastia and preventive therapy or treatment for established gynecomastia should be instituted. Prophylactic radiotherapy has been shown to decrease the incidence of hormone induced gynecomastia by more than 50%. An alternative course of action, which may be more convenient for the patient, is the prophylactic use of tamoxifen. Tamoxifen may also mitigate or resolve gynecomastia during its early or proliferative phase. In severe long-standing gynecomastia surgery is warranted since medical therapies are less likely to succeed. Aromatase inhibitors and 4-hydroxytamoxifen are investigational. Conclusions: Gynecomastia is a significant problem in men undergoing hormonal therapy for prostate cancer. It requires prompt recognition, evaluation and management.

Original languageEnglish (US)
Pages (from-to)1737-1742
Number of pages6
JournalJournal of Urology
Volume174
Issue number5
DOIs
StatePublished - Nov 2005

Fingerprint

Gynecomastia
Prostatic Neoplasms
Incidence
Therapeutics
Hormones
Tamoxifen
Non-Steroidal Estrogens
Nonsteroidal Anti-Androgens
Aromatase Inhibitors
Diethylstilbestrol
Orchiectomy
Radiotherapy
Placebos

Keywords

  • Breast diseases
  • Complications
  • Gynecomastia
  • Prostate
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Incidence and management of gynecomastia in men treated for prostate cancer. / Dobs, Adrian S; Darkes, Malcolm J M.

In: Journal of Urology, Vol. 174, No. 5, 11.2005, p. 1737-1742.

Research output: Contribution to journalArticle

Dobs, Adrian S ; Darkes, Malcolm J M. / Incidence and management of gynecomastia in men treated for prostate cancer. In: Journal of Urology. 2005 ; Vol. 174, No. 5. pp. 1737-1742.
@article{ac2bb4af92b74163a24134e9b154f7af,
title = "Incidence and management of gynecomastia in men treated for prostate cancer",
abstract = "Purpose: Gynecomastia is a potentially treatment limiting adverse event in men receiving hormone therapy for prostate cancer. Materials and Methods: In large, randomized, placebo controlled studies approximately 50{\%} or more of patients with prostate cancer experienced gynecomastia due to multiple mechanisms. Although its severity was mostly reported as mild to moderate, gynecomastia was cited as the reason for most premature withdrawals from therapy. In patients with advanced forms of prostate cancer bilateral orchiectomy was associated with the lowest incidence of gynecomastia, followed by nonsteroidal antiandrogen therapy, diethylstilbestrol and estrogen in rank order. Results: It is important that gynecomastia is well managed in patients with prostate cancer who want to proceed with hormone therapy. Patients should be assessed for the likely etiology of gynecomastia and preventive therapy or treatment for established gynecomastia should be instituted. Prophylactic radiotherapy has been shown to decrease the incidence of hormone induced gynecomastia by more than 50{\%}. An alternative course of action, which may be more convenient for the patient, is the prophylactic use of tamoxifen. Tamoxifen may also mitigate or resolve gynecomastia during its early or proliferative phase. In severe long-standing gynecomastia surgery is warranted since medical therapies are less likely to succeed. Aromatase inhibitors and 4-hydroxytamoxifen are investigational. Conclusions: Gynecomastia is a significant problem in men undergoing hormonal therapy for prostate cancer. It requires prompt recognition, evaluation and management.",
keywords = "Breast diseases, Complications, Gynecomastia, Prostate, Prostatic neoplasms",
author = "Dobs, {Adrian S} and Darkes, {Malcolm J M}",
year = "2005",
month = "11",
doi = "10.1097/01.ju.0000176461.75794.f8",
language = "English (US)",
volume = "174",
pages = "1737--1742",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Incidence and management of gynecomastia in men treated for prostate cancer

AU - Dobs, Adrian S

AU - Darkes, Malcolm J M

PY - 2005/11

Y1 - 2005/11

N2 - Purpose: Gynecomastia is a potentially treatment limiting adverse event in men receiving hormone therapy for prostate cancer. Materials and Methods: In large, randomized, placebo controlled studies approximately 50% or more of patients with prostate cancer experienced gynecomastia due to multiple mechanisms. Although its severity was mostly reported as mild to moderate, gynecomastia was cited as the reason for most premature withdrawals from therapy. In patients with advanced forms of prostate cancer bilateral orchiectomy was associated with the lowest incidence of gynecomastia, followed by nonsteroidal antiandrogen therapy, diethylstilbestrol and estrogen in rank order. Results: It is important that gynecomastia is well managed in patients with prostate cancer who want to proceed with hormone therapy. Patients should be assessed for the likely etiology of gynecomastia and preventive therapy or treatment for established gynecomastia should be instituted. Prophylactic radiotherapy has been shown to decrease the incidence of hormone induced gynecomastia by more than 50%. An alternative course of action, which may be more convenient for the patient, is the prophylactic use of tamoxifen. Tamoxifen may also mitigate or resolve gynecomastia during its early or proliferative phase. In severe long-standing gynecomastia surgery is warranted since medical therapies are less likely to succeed. Aromatase inhibitors and 4-hydroxytamoxifen are investigational. Conclusions: Gynecomastia is a significant problem in men undergoing hormonal therapy for prostate cancer. It requires prompt recognition, evaluation and management.

AB - Purpose: Gynecomastia is a potentially treatment limiting adverse event in men receiving hormone therapy for prostate cancer. Materials and Methods: In large, randomized, placebo controlled studies approximately 50% or more of patients with prostate cancer experienced gynecomastia due to multiple mechanisms. Although its severity was mostly reported as mild to moderate, gynecomastia was cited as the reason for most premature withdrawals from therapy. In patients with advanced forms of prostate cancer bilateral orchiectomy was associated with the lowest incidence of gynecomastia, followed by nonsteroidal antiandrogen therapy, diethylstilbestrol and estrogen in rank order. Results: It is important that gynecomastia is well managed in patients with prostate cancer who want to proceed with hormone therapy. Patients should be assessed for the likely etiology of gynecomastia and preventive therapy or treatment for established gynecomastia should be instituted. Prophylactic radiotherapy has been shown to decrease the incidence of hormone induced gynecomastia by more than 50%. An alternative course of action, which may be more convenient for the patient, is the prophylactic use of tamoxifen. Tamoxifen may also mitigate or resolve gynecomastia during its early or proliferative phase. In severe long-standing gynecomastia surgery is warranted since medical therapies are less likely to succeed. Aromatase inhibitors and 4-hydroxytamoxifen are investigational. Conclusions: Gynecomastia is a significant problem in men undergoing hormonal therapy for prostate cancer. It requires prompt recognition, evaluation and management.

KW - Breast diseases

KW - Complications

KW - Gynecomastia

KW - Prostate

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=27544498812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27544498812&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000176461.75794.f8

DO - 10.1097/01.ju.0000176461.75794.f8

M3 - Article

C2 - 16217274

AN - SCOPUS:27544498812

VL - 174

SP - 1737

EP - 1742

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -